The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course.
| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| ID number | 836 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TACommD@nice.org.uk
| External Assessment Group | Southampton Health Technology Assessments Centre |
Stakeholders
| Companies sponsors | Northwest Biotherapeutics (DCVax-L) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Brain Tumour Charity |
| Brainstrust | |
| International Brain Tumour Alliance (IBTA) | |
| Professional groups | Association of British Neurologists |
| Association of Cancer Physicians | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 September 2018 | Suspended. The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course. |
| 19 September 2018 | The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course. |
| 14 June 2018 | Invitation to participate |
| 03 April 2018 - 01 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 16 August 2017 | As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018 |
| 26 January 2017 - 23 February 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual